Fate Therapeutics, Inc.

DB:F6T Stock Report

Market Cap: €183.4m

Fate Therapeutics Management

Management criteria checks 3/4

Fate Therapeutics' CEO is J. Wolchko, appointed in Dec 2015, has a tenure of 9.17 years. total yearly compensation is $3.52M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth €441.11K. The average tenure of the management team and the board of directors is 6.9 years and 13.8 years respectively.

Key information

J. Wolchko

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage18.3%
CEO tenure9yrs
CEO ownership0.2%
Management average tenure6.9yrs
Board average tenure13.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has J. Wolchko's remuneration changed compared to Fate Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$4mUS$645k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$8mUS$645k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$12mUS$610k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$6mUS$570k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$11mUS$540k

-US$98m

Sep 30 2019n/an/a

-US$86m

Jun 30 2019n/an/a

-US$76m

Mar 31 2019n/an/a

-US$72m

Dec 31 2018US$4mUS$516k

-US$67m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$57m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$1mUS$480k

-US$43m

Compensation vs Market: J.'s total compensation ($USD3.52M) is above average for companies of similar size in the German market ($USD902.55K).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.

CEO

J. Wolchko (54 yo)

9yrs

Tenure

US$3,522,750

Compensation

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015 & serves as It's CFO and CAO since June 3, 2024. Mr. Wolchko ser...

Leadership Team

NamePositionTenureCompensationOwnership
J. Wolchko
Founder9yrsUS$3.52m0.24%
€ 441.1k
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary9.2yrsUS$2.82m0.053%
€ 97.0k
Bahram Valamehr
President of Research & Development6.9yrsUS$2.99m0.067%
€ 122.3k
Jerome Bressi
Chief Regulatory & Quality Officer2.9yrsno data0.24%
€ 444.7k
Andrew Henry
Senior Vice President of Clinical Operationsless than a yearno datano data

6.9yrs

Average Tenure

52.5yo

Average Age

Experienced Management: F6T's management team is seasoned and experienced (6.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
J. Wolchko
Founder9.2yrsUS$3.52m0.24%
€ 441.1k
William Rastetter
Independent Chairman13.1yrsUS$253.25k0.54%
€ 994.1k
John Mendlein
Independent Vice Chairman of the Board16.7yrsUS$218.33k0.27%
€ 501.1k
Robert S. Langer
Member of Scientific Advisory Boardno datano datano data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Robert Epstein
Independent Director10.8yrsUS$228.25k0.010%
€ 18.2k
Stuart Orkin
Member of Scientific Advisory Board14.6yrsno datano data
Sui Huang
Member of Scientific Advisory Board14.6yrsno datano data
Timothy Coughlin
Independent Director11.3yrsUS$231.75k0.058%
€ 106.7k
Sean Morrison
Member of Scientific Advisory Board14.6yrsno datano data
Mark Krasnow
Member of Scientific Advisory Board14.6yrsno datano data
Karin Jooss
Independent Director5.8yrsUS$227.82k0.0086%
€ 15.9k

13.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: F6T's board of directors are seasoned and experienced ( 13.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fate Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research